Pontifax (China) IV L.P., 10% Owner, Director at Keros Therapeutics, Inc. (KROS), sold 6,063,638 shares at $17.75 ($107.6M) on 2025-10-15, disclosed to the SEC on 2025-10-17.
Open-market sale of $107.6M KROS by 10% Owner, Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.75 | 155,262 | $2.8M | 2.6% |
| 2 | $17.75 | 155,262 | $2.8M | 2.6% |
| 3 | $17.75 | 1,121,045 | $19.9M | 18.5% |
| 4 | $17.75 | 1,121,045 | $19.9M | 18.5% |
| 5 | $17.75 | 1,226,412 | $21.8M | 20.2% |
| 6 | $17.75 | 2,284,612 |
| $40.6M |
| 37.7% |
| Total | $17.75 avg | 6,063,638 | $107.6M | 100% |